We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
-0.72%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.6M
AUM Growth
-$49.1M
Cap. Flow
-$48.9M
Cap. Flow %
-3,048.78%
Top 10 Hldgs %
100%
Holding
20
New
1
Increased
–
Reduced
–
Closed
17

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$1.19M

Top Sells

Rank Stock Value
1
BRK.A icon
Berkshire Hathaway Class A
BRK.A
+$31.2M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$2.44M
3
THOR
Synthorx, Inc. Common Stock
THOR
+$2.36M
4
WVE icon
Wave Life Sciences
WVE
+$1.61M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$1.55M

Sector Composition

Rank Sector Weight
1 Consumer Staples 76.39%
2 Healthcare 4.74%
3 Energy 0%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KO icon
1
Coca-Cola
KO
$351B
$1.23M 76.39%
+22,153
New +$1.19M
SPY icon
2
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$303K 18.88%
942
– –
COCP icon
3
Cocrystal Pharma
COCP
$13.1M
$76K 4.74%
12,743
– –
ACA icon
4
Arcosa
ACA
$7.12B
– –
-27,923
Closed -$955K
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-479,902
Closed -$1.38M
BRK.A icon
6
Berkshire Hathaway Class A
BRK.A
$1.06T
– –
-100
Closed -$31.2M
HRTX icon
7
Heron Therapeutics
HRTX
$89.1M
– –
-49,974
Closed -$925K
IFRX icon
8
InflaRx
IFRX
$273M
– –
-36,818
Closed -$91K
MGTX icon
9
MeiraGTx Holdings
MGTX
$1.15B
– –
-81,176
Closed -$1.29M
RYTM icon
10
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-71,856
Closed -$1.55M
TVTX icon
11
Travere Therapeutics
TVTX
$5.27B
– –
-77,180
Closed -$895K
WVE icon
12
Wave Life Sciences
WVE
$1.12B
– –
-78,212
Closed -$1.61M
SMC
13
Summit Midstream
SMC
$407M
– –
-4,697
Closed -$342K
ORTX
14
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-10,869
Closed -$1.29M
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-146,475
Closed -$762K
EIDX
16
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-67,753
Closed -$2.44M
RARX
17
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-59,690
Closed -$1.41M
THOR
18
DELISTED
Synthorx, Inc. Common Stock
THOR
– –
-145,150
Closed -$2.36M
GHDX
19
DELISTED
Genomic Health, Inc.
GHDX
– –
-9,506
Closed -$645K
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
– –
-24,890
Closed -$997K

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q4 2019 Portfolio in Review

As of Q4 2019, Emory University held 20 positions worth $1.6M, down 97% from $50.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Emory University withdrew a net $48.9M in Q4 2019, closing 17 positions. Its most notable exit was Berkshire Hathaway Class A, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 76% of assets, followed by Healthcare and Energy.

Against the trend, Emory University opened a new position in Coca-Cola worth $1.23M.

  • Emory University's largest Q4 2019 buy was Coca-Cola: 22,153 shares worth $1.23M.
  • Emory University fully exited Berkshire Hathaway Class A in Q4 2019, selling an estimated $31.2M.
  • Emory University's ten largest holdings make up 100% of its $1.6M portfolio in Q4 2019.
  • Emory University opened 1 new position and closed 17 in Q4 2019.
  • Emory University's portfolio value fell 97% quarter-over-quarter to $1.6M.

Based on Emory University's 13F filing for Q4 2019, filed 13 Feb 2020.